Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BRTX 
BioRestorative Therapies Inc (BRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/11/2025: BRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.72% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.76M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 112898 | Beta 76.59 | 52 Weeks Range 1.21 - 2.55 | Updated Date 06/18/2025 |
52 Weeks Range 1.21 - 2.55 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -19230.14% |
Management Effectiveness
Return on Assets (TTM) -54.17% | Return on Equity (TTM) -117.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -273339 | Price to Sales(TTM) 32.63 |
Enterprise Value -273339 | Price to Sales(TTM) 32.63 | ||
Enterprise Value to Revenue 5.06 | Enterprise Value to EBITDA 0.13 | Shares Outstanding 7504780 | Shares Floating 4922685 |
Shares Outstanding 7504780 | Shares Floating 4922685 | ||
Percent Insiders 25.54 | Percent Institutions 12.62 |
Analyst Ratings
Rating 4.5 | Target Price 13 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioRestorative Therapies Inc
Company Overview
History and Background
BioRestorative Therapies, Inc. was founded in 2007. It is a biotechnology company focused on stem cell therapies to address unmet needs in orthopedic and metabolic conditions. The company has evolved from initial research and development to clinical trials.
Core Business Areas
- Orthopedics: Development of stem cell therapies for disc degeneration and other orthopedic conditions, primarily through its disc/vertebral bone marrow stem cell platform (ThermoStemu00ae).
- Metabolic Diseases: Exploration of stem cell therapies for metabolic disorders like diabetes through its BRTX-100 product candidate.
Leadership and Structure
The leadership team includes Lance Alstodt as CEO, and the company is structured around clinical research and development, regulatory affairs, and manufacturing.
Top Products and Market Share
Key Offerings
- ThermoStemu00ae: An autologous stem cell therapy in clinical trials for the treatment of chronic lumbar disc disease (CLDD). Market share data is not publicly available as it is still in clinical stages. Competitors include companies developing similar regenerative medicine therapies for disc degeneration and spine conditions, such as Mesoblast, DiscGenics, and various companies in the biologics space.
- BRTX-100: A planned allogeneic stem cell therapy to be studied to treat metabolic disorders, initially targeting type 2 diabetes. Currently in pre-clinical stage and not yet generating revenue. Competitors will be established diabetes treatment providers, and companies developing novel metabolic therapies.
Market Dynamics
Industry Overview
The biotechnology industry is experiencing significant growth, particularly in regenerative medicine and stem cell therapies. There's a high demand for novel treatments for orthopedic and metabolic diseases.
Positioning
BioRestorative Therapies aims to be a leader in regenerative medicine for specific orthopedic and metabolic conditions. Its competitive advantage lies in its proprietary stem cell platform and focus on unmet medical needs.
Total Addressable Market (TAM)
The TAM for stem cell therapies in orthopedics and metabolic diseases is estimated to be billions of dollars. BioRestorative Therapies is positioned to capture a portion of this market pending successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary stem cell platform (ThermoStemu00ae)
- Focus on unmet medical needs
- Clinical-stage assets
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Regulatory hurdles
- Lack of approved products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Increasing demand for regenerative medicine
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger companies
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- MESO
- BMDA
- ICEL
Competitive Landscape
BioRestorative Therapies is smaller than many of its competitors, with limited resources. However, it has a focused approach and proprietary technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the developmental stage of the company.
Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approvals, and commercialization of its therapies. Analyst estimates depend on clinical trial data.
Recent Initiatives: Recent initiatives include advancing the ThermoStemu00ae clinical trial and exploring partnerships for BRTX-100 development.
Summary
BioRestorative Therapies is a high-risk, high-reward biotechnology company focused on stem cell therapies. The company's success hinges on positive clinical trial outcomes and securing sufficient funding. While it has a promising technology platform, it faces significant competition and regulatory hurdles, so watch out for possible financial dilution to shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Industry Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a financial professional. Market share data may be estimated based on available reports and public information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioRestorative Therapies Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2007-07-27 | Chairman of the Board, President & CEO Mr. Lance Alstodt | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.biorestorative.com |
Full time employees 11 | Website https://www.biorestorative.com | ||
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.